Valuation: Protagonist Therapeutics, Inc.

Market Cap 7.86B 6.92B 6.38B 5.97B 11.18B 740B 11.39B 76.66B 29.69B 365B 29.49B 28.85B 1,271B P/E 2026 *
31.3x
P/E 2027 * -102x
Enterprise Value 7.28B 6.41B 5.91B 5.53B 10.36B 686B 10.56B 71.06B 27.52B 339B 27.34B 26.75B 1,178B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 45.6x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -
1 day+2.68%
1 week+9.61%
Current month+22.69%
1 month+23.15%
3 months+21.68%
6 months+37.49%
Current year+39.86%
1 week 113.24
Extreme 113.24
124.8
1 month 92.75
Extreme 92.75
124.8
Current year 77
Extreme 77
124.8
1 year 49.38
Extreme 49.38
124.8
3 years 13.72
Extreme 13.72
124.8
5 years 6.91
Extreme 6.91
124.8
10 years 4.47
Extreme 4.47
124.8
Manager TitleAgeSince
Chief Executive Officer 69 2008-11-30
Director of Finance/CFO 52 2022-04-17
Chief Tech/Sci/R&D Officer - 2026-03-31
Director TitleAgeSince
Director/Board Member 69 2008-11-30
Chairman 71 2014-03-18
Director/Board Member 69 2016-06-30
Date Insider Type Main position Quantity % Market Cap.
06-09Fiscal year

Director

27,000 0.0420%
05-28Fiscal year

Director

27,000 0.0420%
05-11Fiscal year

Chief Executive Officer

225,000 0.3526%
Change 5-day change 1-year change 3-year change Capi.($)
+2.68%+9.61%+127.55%+342.41% 7.65B
+2.56%+7.12%-7.30%-0.26% 44.45B
+0.15%+7.61%+324.11%+565.24% 36.04B
+0.36%+5.50%+3.87%+54.57% 30.7B
+8.37%+8.76%+17.05%-13.29% 28.59B
+7.60%-1.09%+12.49%+20.82% 23.01B
-0.24%+2.97% - - 14.82B
+8.30%+12.19%+62.65%+129.55% 13.52B
+2.73%+7.16%+11.00%+18.45% 12.98B
+0.70%+2.97%+93.04%+93.04% 12.56B
Average +3.32%+4.90%+71.61%+134.50% 22.43B
Weighted average by Cap. +3.20%+5.08%+73.43%+133.24%

Financials

2026 *2027 *
Net sales 509M 448M 414M 387M 725M 48B 738M 4.97B 1.92B 23.68B 1.91B 1.87B 82.38B 160M 141M 130M 121M 227M 15.06B 232M 1.56B 604M 7.43B 600M 587M 25.85B
Net income 258M 227M 210M 196M 367M 24.33B 374M 2.52B 976M 12B 969M 948M 41.76B -87.49M -77.03M -71.05M -66.45M -125M -8.25B -127M -854M -331M -4.07B -328M -321M -14.15B
Net Debt -574M -505M -466M -436M -817M -54.1B -832M -5.6B -2.17B -26.69B -2.15B -2.11B -92.85B -565M -497M -459M -429M -804M -53.23B -819M -5.51B -2.13B -26.26B -2.12B -2.07B -91.36B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
131
Date Price Change Volume
26-06-24 US$122.15 +2.68% 1,132,411
26-06-23 US$118.96 +3.42% 700,455
26-06-22 US$115.03 +1.92% 1,193,688
26-06-18 US$112.86 +1.27% 1,533,672
26-06-17 US$111.44 +0.72% 742,534
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
122.15USD
Average target price
118.69USD
Spread / Average Target
-2.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock